胰高血糖素样肽-1受体激动剂是否破坏脂肪移植?范围综述
本范围综述遵循PRISMA-ScR,综合临床前及临床证据,探讨司美格鲁肽、利拉鲁肽、替尔泊肽及瑞他鲁肽对脂肪细胞代谢、脂肪来源干细胞功能及组织血管化的影响,并映射至脂肪移植成活模型。识别出多个潜在干扰点,但尚无研究直接评估接受肠促胰岛素治疗患者的脂肪移植结局。
要点
- GLP-1 RA可能通过促进脂肪细胞棕色化、增强脂解及抑制ASC成脂分化干扰脂肪移植成活。
- 瑞他鲁肽的胰高血糖素受体激动作用带来额外脂解和产热担忧。
- 目前无直接临床或临床前研究评估GLP-1 RA对脂肪移植结局的影响。
核心结论
- GLP-1 RA可能通过多种机制干扰脂肪移植成活,但缺乏直接证据,需进一步研究。
研究设计与样本
- 范围综述,遵循PRISMA-ScR,综合临床前和临床证据。
主要发现
- GLP-1 RA介导脂肪细胞棕色化和产热激活,上调UCP1和线粒体解偶联。
- GLP-1 RA通过上调ATGL和HSL增强脂解。
- GLP-1 RA抑制ASCs白色成脂分化,偏向产热米色谱系。
- GLP-1 RA调节血管化窗口期的炎症和血管生成信号。
- 瑞他鲁肽通过胰高血糖素受体介导脂解和产热。
临床怎么用
- 围手术期GLP-1 RA管理需基于机制考虑,但推荐仅为假设生成性,非循证指南。
局限性
- 无直接研究评估脂肪移植结局,推荐为假设生成性而非循证指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has created an unprecedented overlap with aesthetic surgery. Millions of patients experiencing GLP-1-mediated weight loss now present with facial volume depletion, soft tissue deflation, and contour irregularities; conditions for which autologous fat grafting remains the gold-standard solution. However, the fundamental biology of GLP-1 receptor agonism may be inherently antagonistic to the mechanisms upon which fat graft survival depends. This scoping review, conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR), synthesizes current preclinical and clinical evidence on the effects of semaglutide, liraglutide, tirzepatide, and the emerging triple agonist retatrutide on adipocyte metabolism, adipose-derived stem cell (ASC) function, and tissue revascularization, and maps these effects onto established models of fat graft take. We identify multiple potential interference points, including GLP-1-mediated adipocyte browning and thermogenic activation with upregulation of uncoupling protein 1 (UCP1) and mitochondrial uncoupling, enhanced lipolysis through adipose triglyceride lipase and hormone-sensitive lipase (HSL) upregulation, suppression of white adipogenic differentiation in ASCs with preferential commitment toward thermogenic beige lineages, and modulation of inflammatory and angiogenic signaling during the critical revascularization window. The growing off-label use of retatrutide in bodybuilding communities introduces additional concerns through glucagon receptor-mediated lipolysis and thermogenesis. Despite the strong mechanistic rationale, no clinical or preclinical studies have directly examined fat graft outcomes in patients receiving incretin-based therapies. We propose a framework for future investigation and offer preliminary, mechanism-based clinical considerations regarding perioperative GLP-1 RA management in fat transfer patients. These recommendations should be understood as hypothesis-generating rather than evidence-based guidelines. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
引用
- Chalhoub X, Ng ZY. Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer. Aesthet Surg J. 2026. PMID: 42219269. doi:10.1093/asj/sjag108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。